FDA opens public input on next animal drug user fee cycle: full analysis

The FDA will hold two virtual public meetings on May 27, 2026, as it starts gathering input on the future of the Animal Drug User Fee Act and the Animal Generic Drug User Fee Act. The meetings are part of the agency’s early reauthorization process for the programs that help fund review of branded and generic animal drugs. FDA announced the meetings on April 28 and said stakeholders can participate through live oral comments or written submissions to the public docket. (fda.gov)

One important point for readers: FDA’s own materials say these programs expire on September 30, 2028, because ADUFA V was reauthorized in 2023 for fiscal years 2024 through 2028. That appears to conflict with the source summary provided here, which said the programs expire September 30, 2026. FDA’s ADUFA program page states the current authorization runs through FY 2028, and the agency framed the May 2026 meetings as input on the “next reauthorization” rather than an imminent 2026 expiration. (fda.gov)

The structure of the meetings reflects FDA’s effort to collect broad early feedback. AGDUFA’s session is scheduled for 11 a.m. to 1 p.m. Eastern, followed by the ADUFA session from 2 p.m. to 4 p.m. Eastern, both by live virtual webcast. People who want to attend must register by midnight Eastern on May 22, 2026, and requests to make an oral presentation were due by May 1. FDA also said the comment dockets for both programs will remain open through December 1, 2027. The relevant docket numbers are FDA-2011-N-0655 for AGDUFA and FDA-2011-N-0656 for ADUFA. (fda.gov)

These programs matter because they underpin part of the FDA’s review capacity for animal drugs. FDA says ADUFA authorizes the agency to collect fees tied to applications, supplements, products, establishments, and sponsors, with those resources supplementing congressional appropriations to support review performance. On the agency’s FY 2026 rate table, the full ADUFA application fee is listed at $708,863, with additional annual fees for establishments, products, and sponsors. In practice, that funding model is meant to improve timeliness and predictability for sponsors bringing new animal drugs and generics to market. (fda.gov)

There’s also a broader policy backdrop. Across FDA, user fee reauthorizations often become the vehicle for operational reforms, not just funding renewals. Regulatory Affairs Professionals Society coverage of other 2025 and 2026 FDA user fee negotiations noted that these cycles historically have created openings for larger FDA reform packages and for industry requests tied to communication, inspection practices, and review efficiency. While that reporting focused on human drug programs, it offers a useful read-through for animal health: stakeholders often use these meetings to push for more predictable review milestones, better meeting structures, and fewer avoidable review cycles. (raps.org)

Industry reaction specific to ADUFA and AGDUFA reauthorization was limited in public search results as of May 8, 2026, but the broader user fee debate remains active. In recent FDA user fee discussions, agency leaders and industry representatives have emphasized that user fees are now central to review program sustainability and access. That doesn’t automatically translate one-for-one to animal health, but it suggests the coming animal drug discussions are likely to center on balancing FDA capacity, sponsor costs, and the need for timely access to new and lower-cost therapies. This is an inference based on the pattern seen in current FDA user fee negotiations and FDA’s own framing of animal drug user fees as support for review timeliness and predictability. (raps.org)

Why it matters: For veterinary professionals, user fee policy can feel distant until it affects the treatment shelf. But the stakes are practical: review resources influence how quickly novel therapies, manufacturing supplements, and generic options become available, which in turn affects formulary choices, supply continuity, and costs passed on to pet parents. If stakeholders use this cycle to argue for process changes at CVM, those changes could shape the drug pipeline well before Congress takes up final legislation. (fda.gov)

What to watch: The next signals will be who shows up at the May 27 meetings, what priorities emerge in the dockets through 2026 and 2027, and when FDA begins formal negotiations that could ultimately produce recommendations for Congress ahead of the current authorization’s September 30, 2028, end date. (fda.gov)